Pricing Log in Create free account

Metagenomi Therapeutics, Inc. (MGX) vs Polyrizon Ltd. (PLRZ)

Metagenomi Therapeutics, Inc. and Polyrizon Ltd. are both Biotechnology companies. Metagenomi Therapeutics, Inc. and Polyrizon Ltd. are of similar size ($27.6M and $27.5M). Across the 7 metrics below, Polyrizon Ltd. leads on 6 and Metagenomi Therapeutics, Inc. on 1.

Valuation

Metric MGX PLRZ Biotechnology median
P/E n/m — 10.60
P/S 1.94 — 9.40
P/B 0.23 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.66 n/m 0.66
EV/Sales (4.72) n/m 9.02
Earnings yield (355.71%) — (32.88%)
Free cash flow yield (325.47%) 0.00% (23.13%)

Profitability

Metric MGX PLRZ Biotechnology median
Gross margin 100.00% — 68.51%
Operating margin (741.58%) — 0.00%
Net margin (689.20%) — 0.00%
Free cash flow margin (632.67%) 0.00% 0.00%
Return on equity (60.61%) 0.00% (51.96%)
Return on assets (41.91%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MGX PLRZ Biotechnology median
Revenue growth (TTM) (59.84%) — 6.76%
EPS growth (last fiscal year) 0.00% 99.39% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric MGX PLRZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.50 36.37 4.97
Net debt to EBITDA 1.71 2.11 1.01

Dividend

Metric MGX PLRZ Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MGX PLRZ Biotechnology median
Market cap 27.60m 27.49m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack